Innovation in bone healing and tissue repair
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
28 Jun 16
valuationLAB Initiates Research Coverage on Kuros
Schlieren (Zurich), Switzerland, June 28, 2016 – Kuros Biosciences Ltd (“Kuros”) today......READ MORE
23 Jun 16
First Trading Day of New Kuros Share after Reverse Split
Schlieren (Zurich), Switzerland, June 23, 2016 – Kuros Biosciences Ltd (“Kuros”) today......READ MORE
Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board
  4. Careers

Products

  1. Pipeline
  2. Sealants
    Surgical sealants
    KUR-023
  3. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News & Events

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
28 Jun 16
valuationLAB Initiates Research Coverage on Kuros
Schlieren (Zurich), Switzerland, June 28, 2016 – Kuros Biosciences Ltd (“Kuros”) today......READ MORE
23 Jun 16
First Trading Day of New Kuros Share after Reverse Split
Schlieren (Zurich), Switzerland, June 23, 2016 – Kuros Biosciences Ltd (“Kuros”) today......READ MORE